News | March 29, 2025
Curium completes acquisition of Monrol
Positions Curium as leading manufacturer of Lu-177 isotope
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
The freshly infused capital will primarily be deployed towards expansion and research & development
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated
